Save the Date: Pioneer in Gene Therapy Announced as Speaker of Next Kriegler Memorial Lecture
Serial entrepreneur Dr. Harry Gruber has been announced as the second speaker of the Rady School's Michael Kriegler Memorial Lecture Series. The engagement will be held January 23, 2012, and is open to Rady School students, faculty, staff and other invited guests.
As one of the pioneers in gene therapy, Dr. Gruber cofounded Tocagen, a company dedicated to the development and commercialization of breakthrough treatments for cancer using advanced gene transfer technology. Previously, he was a founder and/or inventor of the underlying technology for the following public companies, which achieved a combined value over $7 billion: Viagene, Inc. (acquired by Novartis Pharmaceuticals), Gensia Inc. (acquired by Teva Pharmaceutical Industries), INTERVU Inc. (acquired by Akamai Technologies), Kintera Inc. (acquired by Blackbaud) and Metabasis, Inc. (acquired by Ligand Pharmaceuticals). He is the author of more than 100 original scientific articles and an inventor on more than 33 issued and numerous pending patents. Dr. Gruber holds a BA and an MD from the University of Pennsylvania and was trained in internal medicine, biochemical genetics and rheumatology/immunology at UC San Diego, where he subsequently joined the medical school faculty.
The Michael Kriegler Memorial Lecture Series was created by Dr. Kriegler's family to perpetuate his spirit and enthusiasm for science and technology by establishing programs that educate, motivate and inspire Rady School students and faculty. "Michael was an extraordinary person," says Jan Tuttleman of her late husband. "He had a passion for science, learning, discovery and technology. For him, the scientific and technological worlds were his playground."
Further details on the lecture series will be available soon.